Female 68 years old Reason: medullary thyroid CA with mets to liver on clinical trial XL184/cabozantinib trial (IRB16-360), here for f/u (began 2/15/2011).Compare to previous scans History: medullary thyroid CA with mets to liver on clinical trial XL184/cabozantinib trial (IRB16-360), here for f/u (began 2/15/2011).Compare to previous scans ABDOMEN:LIVER, BILIARY TRACT: Again noted are multiple hepatic metastases lesions. Right posterior segment peripheral lesion measures 12 x 12 mm on image #11, series #5, slightly increased in size.More inferior posterior segment lesion measures 11 x 9 mm on image #14, series #5, slightly increased in size compared to previous study.Most inferior index lesion measures 12 x 12 mm on image #19, series #5, grossly unchanged compared to previous study.Anterior segment lesion measures 14 x 10 mm on image #17, series #5, slightly increased in size compared to previous study.There is diffuse low signal in MRI likely secondary to interposition.SPLEEN: No significant abnormality noted.PANCREAS: No significant abnormality noted.ADRENAL GLANDS: No significant abnormality noted.KIDNEYS, URETERS: No significant abnormality noted.RETROPERITONEUM, LYMPH NODES: No significant abnormality noted.BOWEL, MESENTERY: No significant abnormality noted.BONES, SOFT TISSUES: Enhancing right L2 vertebral body lesion is unchanged. Its best seen on image #160, series #14. Enhancing left T12 pedicle lesion on image #137, series #14 is slightly increased in size compared to previous study.OTHER: No significant abnormality noted.
1.Slight interval increase in the size of the most of the hepatic metastases and left T12 pedicle lesion.